WilmerHale Counsels Translate Bio in Initial Public Offering

WilmerHale Counsels Translate Bio in Initial Public Offering

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Translate Bio, Inc., a clinical-stage mRNA therapeutics company developing a new class of medicines to treat diseases caused by protein or gene dysfunction, announced on June 27, 2018 the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross proceeds of approximately $121.6 million. The offering closed on July 2, 2018.

The WilmerHale team counseling Translate Bio through the IPO was led by Cynthia Mazareas and included Susan Murley, Craig Hilts, Timothy Kulis and Michael Lopes.

Read Translate Bio’s press release about the IPO.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel